Literature DB >> 11445802

Genotype/phenotype observations in African Americans with Bartter syndrome.

S J Schurman1, S A Perlman, R Sutphen, A Campos, E H Garin, D N Cruz, L R Shoemaker.   

Abstract

BACKGROUND: Two Bartter syndrome phenotypes have been described, and molecular analyses demonstrate mutations in 1 of 3 genes encoding ascending limb of Henle transporters. We report phenotypic observations in 5 African American children with Bartter syndrome in the context of a distinct genotype.
METHODS: Mutation analyses were performed in 5 unrelated African American children with Bartter syndrome. These results were correlated to clinical and laboratory data. Calcium metabolism was evaluated with a bone disk bioassay.
RESULTS: Mutation analyses demonstrated homozygous deletion of the ClC-Kb gene in all children. Two children had polyhydramnios and premature birth; the others were born at term and presented with failure to thrive or dehydration. All receive indomethacin, spironolactone, and potassium chloride with improved but borderline hypokalemia. Growth has improved with therapy, but height SD scores range from -3.9- to -1.4. Urinary calcium excretion is normal, and bone disk bioassay shows no abnormal calciotropic activity. No patient had nephrocalcinosis, but renal sonograms show loss of corticomedullary differentiation.
CONCLUSIONS: African Americans with Bartter syndrome genotyped to date have homozygous deletion of ClC-Kb Clinical observations in our patients include partial correction of hypokalemia and suboptimal growth despite therapy. Abnormal calciotropic activity and nephrocalcinosis are not seen, but renal ultrasounds are abnormal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445802     DOI: 10.1067/mpd.2001.115020

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  The long-term complications of the inherited tubulopathies: an adult perspective.

Authors:  Maryam Khosravi; Stephen B Walsh
Journal:  Pediatr Nephrol       Date:  2014-02-25       Impact factor: 3.714

2.  Functional severity of CLCNKB mutations correlates with phenotypes in patients with classic Bartter's syndrome.

Authors:  Chih-Jen Cheng; Yi-Fen Lo; Jen-Chi Chen; Chou-Long Huang; Shih-Hua Lin
Journal:  J Physiol       Date:  2017-06-27       Impact factor: 5.182

3.  C1q nephropathy in association with Gitelman syndrome: a case report.

Authors:  Coral Hanevold; Ayesa Mian; Rory Dalton
Journal:  Pediatr Nephrol       Date:  2006-09-06       Impact factor: 3.714

4.  A founder mutation in the CLCNKB gene causes Bartter syndrome type III in Spain.

Authors:  Juan Rodríguez-Soriano; Alfredo Vallo; Gustavo Pérez de Nanclares; José Ramón Bilbao; Luis Castaño
Journal:  Pediatr Nephrol       Date:  2005-05-05       Impact factor: 3.714

Review 5.  Bartter syndrome complicated by immune complex nephropathy. Case report and literature review.

Authors:  Yahya Sardani; Kenan Qin; Mark Haas; Andrew J Aronson; Robert L Rosenfield
Journal:  Pediatr Nephrol       Date:  2003-06-26       Impact factor: 3.714

Review 6.  Longitudinal growth in chronic hypokalemic disorders.

Authors:  Helena Gil-Peña; Natalia Mejia; Oscar Alvarez-Garcia; Vanessa Loredo; Fernando Santos
Journal:  Pediatr Nephrol       Date:  2009-11-10       Impact factor: 3.714

7.  Bartter syndrome: benefits and side effects of long-term treatment.

Authors:  Maria Helena Vaisbich; Maria Danisi Fujimura; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2004-06-16       Impact factor: 3.714

8.  A novel mutation of CLCNKB in a Korean patient of mixed phenotype of Bartter-Gitelman syndrome.

Authors:  Hee-Won Cho; Sang Taek Lee; Heeyeon Cho; Hae Il Cheong
Journal:  Korean J Pediatr       Date:  2016-11-30

9.  Poor phenotype-genotype association in a large series of patients with Type III Bartter syndrome.

Authors:  Alejandro García Castaño; Gustavo Pérez de Nanclares; Leire Madariaga; Mireia Aguirre; Álvaro Madrid; Sara Chocrón; Inmaculada Nadal; Mercedes Navarro; Elena Lucas; Julia Fijo; Mar Espino; Zilac Espitaletta; Víctor García Nieto; David Barajas de Frutos; Reyner Loza; Guillem Pintos; Luis Castaño; Gema Ariceta
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.